PA8496801A1 - Complejo farmaceutico - Google Patents

Complejo farmaceutico

Info

Publication number
PA8496801A1
PA8496801A1 PA20008496801A PA8496801A PA8496801A1 PA 8496801 A1 PA8496801 A1 PA 8496801A1 PA 20008496801 A PA20008496801 A PA 20008496801A PA 8496801 A PA8496801 A PA 8496801A PA 8496801 A1 PA8496801 A1 PA 8496801A1
Authority
PA
Panama
Prior art keywords
complex
pharmaceutical complex
pharmaceutical
sulfobutileter
ciclodextrina
Prior art date
Application number
PA20008496801A
Other languages
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8496801A1 publication Critical patent/PA8496801A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN COMPLEJO DE ELETRIPTAN Y A SULFOBUTILETER-BETA-CICLODEXTRINA, O A SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, Y A PROCEDIMIENTOS PARA LA PREPARACION DE TAL COMPLEJO, INCLUYENDO FORMULACIONES FARMACEUTICAS Y USOS DEL MISMO.
PA20008496801A 1999-06-29 2000-06-06 Complejo farmaceutico PA8496801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
PA8496801A1 true PA8496801A1 (es) 2002-02-21

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008496801A PA8496801A1 (es) 1999-06-29 2000-06-06 Complejo farmaceutico

Country Status (44)

Country Link
US (2) US6713461B1 (es)
EP (1) EP1189640B1 (es)
JP (2) JP4454900B2 (es)
KR (1) KR20020015067A (es)
CN (1) CN1198654C (es)
AP (1) AP2001002369A0 (es)
AR (1) AR033337A1 (es)
AT (1) ATE290884T1 (es)
AU (1) AU770169B2 (es)
BG (1) BG106151A (es)
BR (1) BR0011845A (es)
CA (1) CA2376847C (es)
CO (1) CO5170494A1 (es)
CZ (1) CZ20014572A3 (es)
DE (1) DE60018744T2 (es)
DZ (1) DZ3320A1 (es)
EA (1) EA003908B1 (es)
EC (1) ECSP003551A (es)
EE (1) EE200100697A (es)
ES (1) ES2235879T3 (es)
GB (1) GB9915231D0 (es)
GE (1) GEP20043377B (es)
GT (1) GT200000102A (es)
HR (1) HRP20010951A2 (es)
HU (1) HUP0201629A3 (es)
IL (1) IL146341A0 (es)
IS (1) IS6163A (es)
MA (1) MA26801A1 (es)
MX (1) MXPA01013274A (es)
NO (1) NO20016430L (es)
NZ (1) NZ515235A (es)
OA (1) OA11964A (es)
PA (1) PA8496801A1 (es)
PE (1) PE20010346A1 (es)
PL (1) PL352902A1 (es)
SK (1) SK18932001A3 (es)
SV (1) SV2002000112A (es)
TN (1) TNSN00142A1 (es)
TR (1) TR200103827T2 (es)
UA (1) UA66932C2 (es)
UY (1) UY26224A1 (es)
WO (1) WO2001000243A1 (es)
YU (1) YU87501A (es)
ZA (1) ZA200110454B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
NZ537995A (en) 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU212730B (en) 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
WO1992006973A1 (en) 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
RU2143896C1 (ru) 1993-03-05 2000-01-10 Хексаль Аг Кристаллический комплекс циклодекстрина с гидрохлоридом ранитидина, способ его получения и содержащие его фармацевтические составы
AU2118195A (en) 1994-03-07 1995-09-25 Dendritech Inc. Bioactive and/or targeted dendrimer conjugates
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
CA2257860A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
SK284462B6 (sk) 1997-07-03 2005-04-01 Pfizer Inc. Vodná farmaceutická kompozícia obsahujúca eletriptan hemisulfát a jej použitie
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
NO20016430L (no) 2002-02-26
DZ3320A1 (fr) 2001-01-04
CA2376847C (en) 2007-09-25
MA26801A1 (fr) 2004-12-20
BG106151A (en) 2002-05-31
GB9915231D0 (en) 1999-09-01
EA200101106A1 (ru) 2002-06-27
KR20020015067A (ko) 2002-02-27
HUP0201629A2 (hu) 2003-03-28
AP2001002369A0 (en) 2001-12-31
GEP20043377B (en) 2004-04-13
AU4774100A (en) 2001-01-31
UY26224A1 (es) 2001-01-31
UA66932C2 (en) 2004-06-15
SV2002000112A (es) 2002-02-05
CA2376847A1 (en) 2001-01-04
EE200100697A (et) 2003-02-17
TR200103827T2 (tr) 2002-05-21
ATE290884T1 (de) 2005-04-15
US20040186076A1 (en) 2004-09-23
EA003908B1 (ru) 2003-10-30
IS6163A (is) 2001-11-16
MXPA01013274A (es) 2002-06-04
NZ515235A (en) 2003-08-29
GT200000102A (es) 2001-12-14
ECSP003551A (es) 2002-01-25
JP4454900B2 (ja) 2010-04-21
DE60018744D1 (de) 2005-04-21
PE20010346A1 (es) 2001-03-26
YU87501A (sh) 2004-05-12
ES2235879T3 (es) 2005-07-16
EP1189640A1 (en) 2002-03-27
CN1359303A (zh) 2002-07-17
BR0011845A (pt) 2002-03-05
ZA200110454B (en) 2002-12-20
JP2003503364A (ja) 2003-01-28
TNSN00142A1 (fr) 2005-11-10
CZ20014572A3 (cs) 2002-08-14
WO2001000243A1 (en) 2001-01-04
HUP0201629A3 (en) 2003-11-28
DE60018744T2 (de) 2006-05-18
HRP20010951A2 (en) 2005-04-30
PL352902A1 (en) 2003-09-22
OA11964A (en) 2006-04-17
IL146341A0 (en) 2002-07-25
JP2006257091A (ja) 2006-09-28
AR033337A1 (es) 2003-12-17
SK18932001A3 (sk) 2002-09-10
EP1189640B1 (en) 2005-03-16
CN1198654C (zh) 2005-04-27
US6713461B1 (en) 2004-03-30
NO20016430D0 (no) 2001-12-28
AU770169B2 (en) 2004-02-12
CO5170494A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
PA8503601A1 (es) Derivados de purina
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
PA8548701A1 (es) Azaindoles
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
DE60114635D1 (de) Pharmazeutische formulierungen
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
MX9300399A (es) Derivados heterotriciclicos.
PA8496801A1 (es) Complejo farmaceutico
PT1150704E (pt) Melagatran para o tratamento da inflamacao
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
ECSP034632A (es) Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor